Table 1 Study characteristics
Study | Country | Multi-center | Study design | Age (yr)a | N | Male (%)a | Surgery | NOS scores |
|---|---|---|---|---|---|---|---|---|
Mikus, 2021 [20] | Germany | No | Cohort | 6.5 ± 6.0 vs. 7.3 ± 6.2 (months) b | 803 | 100 vs. 100 | Cardiac Catheterization | 9 |
Zaouter, 2018 [21] | France | No | Cohort | 80.2 ± 7.5 vs. 81.8 ± 8.4b | 234 | 48.5 vs. 51.2 | TAVI | 8 |
Weyland, 2021 [22] | Switzerland | No | Cohort | 76 (64, 81) vs. 75 (66, 82)c | 105 | 68.3 vs. 46.7 | Endovascular stroke treatment | 8 |
Toppen, 2017 [23] | USA | No | Matched cohort | 82.4 ± 11 vs. 83.5 ± 9b | 196 | 50.3 vs. 46.9 | TAVR | 8 |
Thiele, 2020 [8] | Germany | Yes | RCT | 81.4 ± 5.7 vs. 81.8 ± 5.3b | 437 | 48.6 vs. 49.1 | TAVI | 𝛿 |
Theron, 2014 [24] | UK | No | Cohort | 64.6 ± 12.9 vs. 68 ± 10.6b | 183 | 83.2 vs. 88.2 | Implantation of Pacing Device | 8 |
Téllez-Alarcón, 2022 [25] | Brazil | No | Cohort | 78.1 (75.8, 80.4) vs. 80.4 (78.9, 81.9)d | 158 | 55.6 vs. 48.8 | TAVI | 8 |
Stragier, 2019 [26] | Belgium | No | Cohort | 81.7 (80.0, 83.5) vs. 81.3 (79.6, 83.1)d | 178 | 48.2 vs. 53.8 | TAVI | 8 |
Shan, 2018 [27] | China | Yes | Matched cohort | 63.5 (54.5, 74.3) vs. 65.5 (59, 72.3)c | 228 | 66.7 vs. 61.4 | Endovascular thrombectomy | 8 |
Schönenberger, 2016 [28] | Germany | No | RCT | 71.8 ± 12.9 vs. 71.2 ± 14.7b | 150 | 65.8 vs. 54.5 | Endovascular thrombectomy | 𝛿 |
Palermo, 2016 [29] | USA | No | Cohort | 79.6 ± 0.9 vs. 85.4 ± 9.1b | 65 | 76.2 vs. 68.2 | TAVI | 7 |
Sammour, 2021 [7] | USA | No | Cohort | 80 ± 10.2 vs. 81 ± 9b | 998 | 56.1 vs. 41.8 | TAVR | 9 |
Renner, 2019 [30] | Germany | No | Cohort | 82 ± 6.1 vs. 82 ± 6.4b | 200 | 41.1 vs. 51.6 | TAVI | 8 |
Ren, 2020 [31] | China | No | RCT | 69.21 ± 5.78 vs. 69.19 ± 6.46b | 90 | 54.2 vs. 57.1 | Endovascular thrombectomy | 𝛿 |
Rassaf, 2014 [32] | Germany | No | Cohort | 75 ± 8.7 vs. 74.5 ± 8b | 21 | 63.6 vs. 90 | Percutaneous mitral valve repair | 6 |
Powers, 2019 [33] | USA | Yes | RCT | 69.5(59, 78) vs. 70.5(59, 79)c | 92 | 54 vs. 48 | Endovascular thrombectomy | 𝛿 |
Piayda, 2021 [34] | Germany | Yes | Cohort | 75 ± 8 vs. 75 ± 9b | 949 | 67.1 vs. 62.9 | Transcatheter left atrial appendage closure | 8 |
Patzelt, 2017 [35] | Germany | No | Cohort | 74 ± 10 vs. 78 ± 8b | 271 | 62.5 vs. 43.7 | Percutaneous mitral valve repair (PMVR) | 7 |
Pani, 2017 [36] | USA | No | Cohort | 83 (78, 89) vs. 83 (77, 88)c | 97 | 51 vs. 55 | TAVR | 8 |
Musuku, 2021 [37] | USA | No | Matched cohort | 81 (74, 86) vs. 83 (76, 88)c | 296 | 55 vs. 48 | TAVR | 9 |
Mosleh, 2019 [38] | USA | No | Matched cohort | 80.31 ± 9.31 vs. 82.06 ± 7.41b | 308 | 57.8 vs. 46.8 | TAVI | 9 |
Miles, 2016 [39] | UK | No | Cohort | 77.8 ± 7.8 vs. 81.5 ± 6.4b | 88 | 75 vs. 66 | TAVI | 7 |
McDonald, 2015 [40] | USA | No | Matched cohort | 71 (58, 80) vs. 70 (58, 79)c | 1014 | 48.7 vs. 44.2 | Endovascular thrombectomy | 9 |
Mayr, 2016 [41] | Germany | No | RCT | 80 (75, 84) vs. 84 (79, 86)c | 62 | 41.9 vs. 58.1 | TAVI | 𝛿 |
Löwhagen, 2017 [42] | Sweden | No | RCT | 73 (65, 80) vs. 72 (66, 82)c | 90 | 58 vs. 51 | Endovascular thrombectomy | 𝛿 |
Kleinecke, 2021 [43] | Germany | Yes | Matched cohort | 77.0 ± 6.8 vs. 78.0 ± 7.3b | 311 | 63.5 vs. 51 | Transcatheter left atrial appendage closure | 7 |
Kislitsina, 2019 [44] | USA | No | Cohort | 81.9 ± 10.6 vs. 81.2 ± 9.2b | 286 | NA | TAVR | 7 |
Kiramijyan, 2016 [45] | USA | No | Cohort | 81.3 ± 10.6 vs. 82.9 ± 7.6b | 533 | 50 vs. 50.6 | TAVR | 8 |
Jumaa, 2010 [46] | USA | No | Cohort | 66.47 vs. 66.6e | 126 | 41.5 vs. 53.4 | Endovascular Acute Stroke Therapy | 8 |
John, 2014 [47] | USA | No | Cohort | 64.8 ± 17 vs. 69.1 ± 13.5b | 190 | 40.7 vs. 46.5 | Intra-arterial thrombolysis | 8 |
Jadhav, 2017 [48] | USA | No | Matched cohort | 67 (55.5, 78.5) vs. 69 (60, 75)c | 122 | 41 vs. 54.1 | Endovascular Acute Stroke Therapy | 9 |
Hyman, 2017 [49] | USA | Yes | Cohort | 81.8 ± 8.4 vs. 82.4 ± 8.2b | 10,997 | 53.7 vs. 54.2 | TAVR | 8 |
Husser, 2018 [50] | Germany | Yes | Matched cohort | 81 ± 5 vs. 81 ± 6b | 5248 | 41.8 vs. 41.4 | TAVR | 9 |
Herrmann, 2021 [51] | USA | Yes | Cohort | 80.5 ± 7.3 vs. 76.6 ± 7.4b | 1443 | 53.8 vs. 61.6 | TAVR | 7 |
Haurand, 2022 [52] | Germany | Yes | Cohort | 80 (76, 84) vs. 81 (77, 83)c | 104 | 50.0 vs. 35 | TAVR | 7 |
Harjai, 2020 [53] | Australia | Yes | Cohort | 82 (77, 87) vs. 83 (77, 87)c | 477 | 51.1 vs. 49.2 | TAVI | 7 |
Griessenauer, 2017 [54] | USA | Yes | Matched cohort | 60.5 (29, 76) vs. 60 (29, 80)c | 140 | 14.3 vs. 14.3 | Flow diversion for cerebral aneurysm | 7 |
Feil, 2021 [55] | Germany | No | Cohort | 73.1 ± 13.1 vs. 73.4 ± 13.0b | 6103 | 49.1 vs. 49.4 | Endovascular thrombectomy | 7 |
Du, 2020 [56] | China | No | Cohort | 60 ± 10 vs. 60 ± 11b | 178 | 87.1 vs. 74.4 | Endovascular thrombectomy | 8 |
D'Errigo, 2016 [57] | Italy | Yes | Matched cohort | 82.0 ± 5.4 vs. 82.7 ± 5.8b | 620 | 61.9 vs. 64.5 | TAVR | 7 |
Cappellari, 2020 [58] | Italy | Yes | Cohort | 72 (59, 79) vs. 74 (63, 81)c | 3298 | 55 vs. 47.2 | Endovascular thrombectomy | 8 |
Ben-Dor, 2012 [59] | USA | No | Cohort | 83.7 ± 7.9 vs. 84.1 ± 5.1b | 92 | 36.4 vs. 41.4 | TAVR | 8 |
Althoff, 2021 [60] | USA | No | Cohort | 65 (52, 77) vs. 65 (53, 78)c | 17,538 | 50.5 vs. 46.5 | ERCP | 9 |
Yamamoto, 2013 [61] | France | No | Cohort | 84.7 ± 7.0 vs. 83.7 ± 7.1b | 174 | 46.7 vs. 39.5 | TAVI | 8 |
Hoefnagel, 2023 [62] | USA | No | Cohort | 65 (55, 75) vs. 68 (60, 76)c | 125 | 50 vs. 59.5 | Endovascular thrombectomy | 8 |
Reda, 2012 [63] | Australia | No | Cohort | 83.4 ± 0.6 vs. 82.6 ± 1.2b | 74 | 54.5 vs. 34.1 | TAVI | 8 |
Neumann, 2020 [64] | UK | Yes | Cohort | 81.3 ± 6.60 vs. 81.9 ± 6.72b | 1694 | 51.6 vs. 50.2 | TAVR | 7 |
Skutecki, 2022 [65] | France | Yes | Matched cohort | 68 ± 13 vs. 68 ± 13b | 258 | 63.6 vs. 61.2 | Endovascular thrombectomy | 9 |
Liang, 2021 [66] | China | No | Cohort | 75.74 ± 7.05 vs. 76.95 ± 5.61b | 134 | 66.7 vs. 58.9 | TAVR | 8 |
Valente, 2021 [67] | Portugal | No | Cohort | 79 (71, 84) vs. 82 (76, 85)c | 107 | 54.2 vs. 30.1 | TAVI | 7 |
Kanda, 2022 [68] | Japan | No | Cohort | 61.9 ± 13.6 vs. 81.6 ± 10.9b | 101 | 49 vs. 29 | Minimally invasive mitral valve surgery | 7 |
Holmes, 2022 [69] | USA | No | Cohort | 77 vs. 77.6e | 166 | 97.6 vs. 97.6 | TAVR | 8 |
Liang, 2022 [70] | China | No | RCT | 64 ± 11 vs. 60 ± 13b | 87 | 76.7 vs. 86.4 | Endovascular thrombectomy | 𝛿 |
Maurice, 2022 [71] | France | Yes | RCT | 70.8 ± 13.0 vs. 72.6 ± 12.3b | 345 | 52.7 vs. 56.3 | Endovascular thrombectomy | 𝛿 |
Sanders, 2021 [72] | USA | No | Cohort | 81 (74, 86) vs. 80 (73, 86)c | 79 | 36.8 vs. 53.7 | TAVR | 8 |
Monaco, 2022 [73] | Italy | No | Matched cohort | 73 (68, 78) vs. 72 (67–76)c | 84 | 71 vs. 69 | Endovascular repair of thoracic-abdominal aortic aneurysms | 9 |
Goren, 2015 [74] | Israel | No | Cohort | 83 ± 5.5 vs. 83 ± 5.4b | 204 | 36 vs. 40 | TAVI | 8 |
Aslan, 2021 [75] | Turkey | No | Cohort | 77.8 ± 6.9 vs. 78.1 ± 8.9b | 72 | 31 vs. 30 | TAVI | 8 |